We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders

By LabMedica International staff writers
Posted on 01 Apr 2024

Alterations in human DNA range from minor single nucleotide variations to substantial alterations involving the deletion or duplication of extensive DNA segments, known as copy number variations (CNVs). More...

While CNVs contribute significantly to human genetic diversity and are often harmless, they can also lead to various neurodevelopmental disorders like Angelman syndrome, DiGeorge syndrome, and Williams-Beuren syndrome. Children suspected of having genetic conditions due to these significant DNA deletions or duplications typically undergo a lengthy diagnostic process that begins with microarray testing and may advance to more comprehensive genome-wide sequencing tests, such as exome or genome sequencing. Detecting CNVs in sequencing data and interpreting them can be challenging for clinical teams, which is why microarrays are commonly employed. Scientists have now created a single approach to identify these structural alterations using data from genome-wide exome sequencing assays.

The findings of the study by researchers from the Wellcome Sanger Institute (Cambridgeshire, UK) along with their collaborators suggest that a genetic test could be capable of replacing the existing dual-step diagnostic approach for identifying rare developmental disorders in children. This advancement could facilitate earlier diagnoses for affected families and save critical healthcare resources. The team reevaluated genetic information from approximately 10,000 families involved in the Deciphering Developmental Disorders study. They devised a single-assay technique that integrates four algorithms using machine learning to examine exome sequencing data.

The team demonstrated for the first time that exome sequencing, which only reads only protein-coding DNA, is equally or more accurate than standard clinical microarrays at identifying disease-causing structural genetic variations. Upon comparing this innovative single-assay method against the usual clinical methods, the researchers found it could accurately identify 305 significant pathogenic mutations, including 91 that were undetectable by standard clinical microarrays previously. These results indicate the potential of this method to replace existing diagnostic procedures, offering quicker, more accurate detection of rare genetic diseases, and potentially leading to significant savings for healthcare systems. However, the implementation of this approach may require additional training for specialists to efficiently generate and analyze the data, according to the researchers.

“We are still learning how large-scale genetic variations impact human health. This study proves that with the right computational methods, a single test can accurately detect them,” said Professor Matthew Hurles, Director of the Wellcome Sanger Institute and senior author of the study.

Related Links:
Wellcome Sanger Institute


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.